ABSTRACT. The effects of a timolol maleate gel-forming solution (TMGS) on intraocular pressure (IOP), blood pressure (BP), and pupil size (PS) were evaluated in normotensive dogs. TMGS was administered once daily to six normotensive beagle dogs. TMGS administration reduced IOP and PS. The hypotensive effect persisted for 24 hr after the administration. The mean reduction in IOP was 5.3 mm Hg (P<0.01). The changes in BP and PS were not significant. These results suggest that TMGS can potentially be used in the treatments of glaucoma and ocular hypertension in dogs. KEY WORDS: canine, gellan gum, timolol.J. Vet. Med. Sci. 68(6): 631-633, 2006 Glaucoma is a painful disease and is characterized by retinal ganglion cell death, optic nerve damage that is usually associated with elevated intraocular pressure (IOP), and progressive loss of vision that could result in blindness. Glaucoma therapy aims to lower IOP in order to preserve ocular function and reduce pain [1].Timolol maleate (TM) is a nonselective beta-adrenergic that substantially reduces the volume of aqueous humor and thereby reduces IOP [1,3,20]. TM ophthalmic solution is widely used to treat glaucoma in humans and dogs. However, TM has the potential to cause systemic side effects [4, 6, 8-10, 15-17, 19, 20]. The TM gel-forming solution (TMGS) is delivered in a gellan gum solution and can be administered to the eye as a drop; this drop forms a viscous solution on contact with the ocular surface. TMGS holds TM for a longer period of time than the TM aqueous solution; consequently, TMGS is administered once daily [2,10,[12][13][14]. In this study, we evaluated the effects of TMGS on IOP, systolic and diastolic blood pressure (BP), and pupil size (PS) in normotensive beagle dogs.All animals were treated in accordance with the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research. Six clinically normal beagle dogs (two males and four females) were used in this study. Their body weights ranged from 9.7 to 13.0 kg (median weight: 12.2 kg), and their ages ranged from 4 to 11 years (median age: 8.0 years). Dogs were defined as normotensive after a complete physical and ophthalmic examination, including tonometry, slit-lamp biomicroscopy, and ophthalmoscopy; these examinations did not reveal any abnormalities. A 0.5% TMGS (Timoptol XE 0.5%, Banyu Pharmaceutical Co., Ltd., Tokyo) was used in this study. TMGS was administered in one eye (treated eye) of each dog. Once-a-day administration (9:00 AM) was continued for 7 days. The contralateral eyes (nontreated eyes) were not treated. IOP was measured using an applanation tonometer (Tono-Pen XL, Medtronic, FL, U.S.A.); BP, an oscillometric hematomanometer (BP100D, Fukuda M-E Kogyo Co., Ltd., Tokyo, Japan); and PS, a pupillometer (Mita's pupillometer, Inami, Tokyo, Japan). IOP, BP, and PS were measured before administration of TMGS; 1, 2, 4, 6, 10, and 24 hr after administration on the first day; and at 7:00 PM everyday from the second day until the en...